

# John Gierula

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2197382/publications.pdf>

Version: 2024-02-01

48  
papers

734  
citations

623734

14  
h-index

552781

26  
g-index

48  
all docs

48  
docs citations

48  
times ranked

1306  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of Vitamin D on Cardiac Function in Patients With Chronic HF. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2593-2603.	2.8	179
2	Prevalence and Predictors of Sepsis Death in Patients With Chronic Heart Failure and Reduced Left Ventricular Ejection Fraction. <i>Journal of the American Heart Association</i> , 2018, 7, e009684.	3.7	52
3	Predicting one-year mortality in heart failure using the "Surprise Question": a prospective pilot study. <i>European Journal of Heart Failure</i> , 2019, 21, 227-234.	7.1	40
4	Infection-Related Hospitalization in Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006746.	3.9	39
5	Chronotropic Incompetence Does Not Limit Exercise Capacity in Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1885-1896.	2.8	32
6	Prioritizing symptom management in the treatment of chronic heart failure. <i>ESC Heart Failure</i> , 2020, 7, 2193-2207.	3.1	32
7	Mortality Reduction Associated With $\beta^2$ -Adrenoceptor Inhibition in Chronic Heart Failure Is Greater in Patients With Diabetes. <i>Diabetes Care</i> , 2018, 41, 136-142.	8.6	32
8	Cardiac resynchronization therapy in pacemaker-dependent patients with left ventricular dysfunction. <i>Europace</i> , 2013, 15, 1609-1614.	1.7	31
9	Vitamin D deficiency is an independent predictor of mortality in patients with chronic heart failure. <i>European Journal of Nutrition</i> , 2019, 58, 2535-2543.	3.9	23
10	Calcium, phosphate and calcium phosphate product are markers of outcome in patients with chronic heart failure. <i>Journal of Nephrology</i> , 2015, 28, 209-215.	2.0	21
11	Association of heart failure and its comorbidities with loss of life expectancy. <i>Heart</i> , 2021, 107, 1417-1421.	2.9	21
12	Ambulatory heart rate range predicts mode-specific mortality and hospitalisation in chronic heart failure. <i>Heart</i> , 2016, 102, 223-229.	2.9	20
13	Chronic heart failure with diabetes mellitus is characterized by a severe skeletal muscle pathology. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 394-404.	7.3	20
14	Advanced care planning during the COVID-19 pandemic: ceiling of care decisions and their implications for observational data. <i>BMC Palliative Care</i> , 2021, 20, 10.	1.8	18
15	Divergent skeletal muscle mitochondrial phenotype between male and female patients with chronic heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 79-88.	7.3	15
16	Rate-Response Programming Tailored to the Force-Frequency Relationship Improves Exercise Tolerance in Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 105-113.	4.1	14
17	To the Editor "New phones, old problem? Interference with cardiovascular implantable electronic devices by phones containing magnets. <i>Heart Rhythm</i> , 2021, 18, 1041.	0.7	13
18	Pacing-associated left ventricular dysfunction? Think reprogramming first!. <i>Heart</i> , 2014, 100, 765-769.	2.9	12

#	ARTICLE	IF	CITATIONS
19	Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure. <i>Circulation</i> , 2020, 141, 1693-1703.	1.6	12
20	Unique Transcriptome Signature Distinguishes Patients With Heart Failure With Myopathy. <i>Journal of the American Heart Association</i> , 2020, 9, e017091.	3.7	11
21	Patients with long-term permanent pacemakers have a high prevalence of left ventricular dysfunction. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 743-750.	1.5	10
22	Cardiac resynchronization therapy outcomes in patients with chronic heart failure. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 962-967.	1.5	10
23	Cardiac contractility modulation for the treatment of heart failure with reduced ejection fraction. <i>Heart Failure Reviews</i> , 2021, 26, 217-226.	3.9	10
24	Ischemic Heart Disease Modifies the Association of Atrial Fibrillation With Mortality in Heart Failure With Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2018, 7, e009770.	3.7	9
25	Prognostic Significance of Incidental Nonsustained Ventricular Tachycardia Detected on Pacemaker Interrogation. <i>American Journal of Cardiology</i> , 2019, 123, 409-413.	1.6	8
26	Effect of disease-modifying agents and their association with mortality in multi-morbid patients with heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2020, 7, 3859-3870.	3.1	7
27	Septal Pacing: Still No Clarity?. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2014, 37, 263-264.	1.2	6
28	Impact of QRS duration on left ventricular remodelling and survival in patients with heart failure. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 848-856.	1.5	6
29	Feasibility and validation of trans-valvular flow derived by four-dimensional flow cardiovascular magnetic resonance imaging in pacemaker recipients. <i>Magnetic Resonance Imaging</i> , 2020, 74, 46-55.	1.8	5
30	Response to (resynchronization) therapy in chronic heart failure: time for a different approach. <i>European Journal of Heart Failure</i> , 2014, 16, 117-118.	7.1	4
31	Performance of 2014 NICE defibrillator implantation guidelines in heart failure risk stratification. <i>Heart</i> , 2016, 102, 735-740.	2.9	3
32	Devices in heart failure; diagnosis, detection and disease modification. <i>British Medical Bulletin</i> , 2018, 125, 91-102.	6.9	3
33	Prospective evaluation and long-term follow-up of patients referred to secondary care based upon natriuretic peptide levels in primary care. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2019, 5, 218-224.	4.0	3
34	Detrimental Immediate- and Medium-Term Clinical Effects of Right Ventricular Pacing in Patients With Myocardial Fibrosis. <i>Circulation: Cardiovascular Imaging</i> , 2021, 14, e012256.	2.6	3
35	Optimising pacemaker therapy and medical therapy in pacemaker patients for heart failure: protocol for the OPT-PACE randomised controlled trial. <i>BMJ Open</i> , 2019, 9, e028613.	1.9	2
36	Impact of the COVID-19 pandemic on the management of chronic heart failure. <i>Reviews in Cardiovascular Medicine</i> , 2021, 22, 271.	1.4	2

#	ARTICLE	IF	CITATIONS
37	Quantifying the relationship and contribution of mitochondrial respiration to systemic exercise limitation in heart failure. ESC Heart Failure, 2021, 8, 898-907.	3.1	2
38	Cardiac magnetic resonance in patients with cardiac resynchronization therapy: is it time to scan with resynchronization on?. Europace, 2019, 21, 554-562.	1.7	1
39	Long-term performance of left ventricular leads in cardiac resynchronisation therapy. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 1501-1507.	1.2	1
40	Diabetes, gender and deterioration in estimated glomerular filtration rate in patients with chronic heart failure: Ten-year prospective cohort study. Diabetes and Vascular Disease Research, 2021, 18, 147916412098443.	2.0	1
41	Diabetes mellitus and the causes of hospitalisation in people with heart failure. Diabetes and Vascular Disease Research, 2022, 19, 147916412110739.	2.0	1
42	Reply. Journal of the American College of Cardiology, 2016, 68, 1253.	2.8	0
43	A CARDIOMETABOLIC RESERVE IN HEART FAILURE, REVEALED BY VERIFICATION PHASE EXERCISE TESTING, DOES NOT CONFER PROGNOSTIC BENEFIT. Chest, 2020, 158, A2056-A2057.	0.8	0
44	We Do Not Talk to Patients About Their Prognosis, But Is Any of This Surprising?. Journal of Cardiac Failure, 2021, 27, 1479-1480.	1.7	0
45	Advances in cardiac resynchronization and implantable cardioverter/defibrillator therapy: Medtronic Cobalt and Crome. Future Cardiology, 2021, 17, 609-618.	1.2	0
46	OUP accepted manuscript. Europace, 2021, , .	1.7	0
47	Response by Gierula et al to Letter Regarding Article, "Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure: A Phase II Study". Circulation, 2020, 142, e319-e320.	1.6	0
48	Personalised reprogramming to prevent progressive pacemaker-related left ventricular dysfunction: A phase II randomised, controlled clinical trial. PLoS ONE, 2021, 16, e0259450.	2.5	0